Rare tumors and peritoneal mesothelioma

Introduction

Some uncommon tumors can affect the peritoneum and cause carcinomatosis or malignant ascites. Because these are rare diseases, they often bring uncertainty, and the information available about them is limited.

In some very carefully selected cases, these tumors may benefit from cytoreductive surgery, alone or combined with HIPEC. However, not all patients are candidates, and the decision must be made with great caution and experience.

What do we mean by rare tumors with peritoneal involvement?

This group includes several different diseases, among them:

• Peritoneal mesothelioma
• Peritoneal sarcomatosis, such as from uterine leiomyosarcoma
• Peritoneal carcinomatosis of breast origin
• Peritoneal carcinomatosis from the gallbladder
• Malignant ascites caused by a tumor

Each of these diseases behaves differently, so they cannot all be treated in the same way.

Peritoneal mesothelioma

Peritoneal mesothelioma is an uncommon tumor that starts in the peritoneum itself.

The type of mesothelioma, how far it has spread and the patient's general condition must be assessed before this treatment is recommended.

Peritoneal sarcomatosis

Some sarcomas, such as uterine leiomyosarcoma, can spread to the peritoneum.

In these cases:

• The disease is usually more aggressive
• Extensive surgery does not always bring a benefit

However, in very carefully selected cases with limited, controlled disease, cytoreductive surgery with or without HIPEC may be considered, as part of an individualized and cautious approach.

Peritoneal carcinomatosis from breast cancer

Peritoneal involvement in breast cancer is uncommon.

In most cases:

• The main treatment is systemic (chemotherapy, hormone therapy or targeted therapies)
• In very specific situations, with isolated peritoneal disease and good overall control, surgery may be considered as part of an exceptional and highly individualized approach

Gallbladder and other rare digestive tumors

Peritoneal carcinomatosis originating in the gallbladder or in other rare digestive tumors usually behaves aggressively.

For this reason:

• Surgery with HIPEC is only considered in very carefully selected cases
• Always after carefully weighing the risks and benefits
• The aim is to avoid very aggressive surgery when there is no reasonable expectation of benefit

Malignant ascites: can it be treated with surgery?

Malignant ascites is a buildup of fluid in the abdomen caused by the tumor.

In most cases:

• Treatment is palliative and aimed at symptoms
• It focuses on improving quality of life

In exceptional situations, when the ascites is related to peritoneal disease that can be controlled, a more active treatment may be considered, always after an expert assessment.

Why does patient selection matter so much?

With these tumors, more than with any other group, selecting the right patients is what prevents harm.

Before recommending surgery or HIPEC, the team assesses:

• The exact type of tumor
• How aggressive it is
• How far the disease has spread
• Response to previous treatments
• The patient's general condition

How long will I be in hospital?

• Limited procedures: Short stay
• Extensive cytoreductions: 10-15 days, or longer in complex cases